Immunogenic efficacy of differently produced recombinant vaccines candidates against Pseudomonas aeruginosa infections

J Biotechnol. 2000 Sep 29;83(1-2):3-12. doi: 10.1016/s0168-1656(00)00311-4.


Three different variants of the recombinant hybrid outer membrane protein OprF (aa 190-342)-OprI (aa 21-83) could be obtained in high yield after expression in Escherichia coli. The hybrid protein was modified N terminally, either with a minimal histidine tag or with a homologous sequence of OprF. Both recombinant proteins were purified by nickel chelate affinity chromatography under native and denaturing conditions, and this produced three suitable candidates for a vaccination trial, protein His-F-I, which was purified in its native as well as in its refolded form; and the native purified N terminally extended protein, ex-F-I. In mice, significantly higher antibody titers and survival rates after challenge with Pseudomonas aeruginosa were observed following immunization with protein His-F-I, purified under native conditions.

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibodies, Bacterial / biosynthesis
  • Chromatography, Affinity
  • Escherichia coli / genetics
  • Fluorescent Antibody Technique
  • Glutathione Transferase / genetics
  • Mice
  • Molecular Sequence Data
  • Porins / chemistry
  • Porins / genetics
  • Porins / isolation & purification
  • Pseudomonas Infections / immunology
  • Pseudomonas Infections / prevention & control*
  • Pseudomonas aeruginosa / immunology*
  • Recombinant Fusion Proteins / chemistry
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / isolation & purification
  • Vaccines, Synthetic / immunology*


  • Antibodies, Bacterial
  • Porins
  • Recombinant Fusion Proteins
  • Vaccines, Synthetic
  • Glutathione Transferase